Abbvie förvärvar lovande projekt inom psykisk ohälsa

Abbvie köper ett läkemedelsprogram inom mental hälsa i en miljardaffär som ser lite annorlunda än vad som tidigare uppgetts.

The FDA’s new transparency policy (Part 3)

As transparency and consistency become increasingly emphasized by the FDA, medical device manufacturers must approach their submissions with both thoroughness a...

Hypothesis testing versus conspiracy theory

"How do you know what is a conspiracy theory and what is a reasonable, scientifically based conclusion?" In a column, Ingrid Lönnstedt reflects on this question.

Abbvie ryktas överväga miljardförvärv inom mental hälsa

Läkemedelsbolaget Abbvie uppges föra diskussioner om att förvärva Gilgamesh Pharmaceuticals, ett bolag inom mental hälsa, i en affär som ska ligga på omkring en miljard dollar.

Innovative start-up helps doctors, scientists and industry balance coagulation risks

For many doctors caring for seriously ill patients, for example, in stroke units and cancer wards, maintaining the life-saving balance between bleeding and thro...

Anocca raises SEK 440 million ahead of clinical cancer trial

Swedish cell therapy biotech Anocca has successfully raised SEK 440 million in a new funding round to support upcoming clinical trials in pancreatic cancer.

ZEISS announces CE mark for CIRRUS PathFinder AI tool with automated OCT assessment

Fully integrated AI decision support tool flags B scans that may require further review, supporting more confident decision making and more efficient patient care.

Controlled Pneumatics: pushing the boundaries of pneumatics

automation processes that are already known. It also opens up new opportunities, especially for controlling pressure and flow rate. Piezo valves, which enable v...

Life science trends 2025 – Neurology

New Alzheimer's drugs are beginning to be used in Sweden, more deals in the neuro sector are expected, and tools for deliver active substances across the blood-...

Explore 3D Testing of Deformation and Motions

Powerful measurement capabilities with the new ZEISS ARAMIS 1.

Phase III win for Hansa Biopharma: “We Are Thrilled”

Swedish biotech Hansa Biopharma’s transplant drug imlifidase has met the primary efficacy endpoint in a registration-enabling Phase III study in the United States.

Lilly´s Nordic manager on Mounjaro launch in Sweden: "Patients deserve respect"

Another blockbuster diabetes and obesity drug has made its way into the Swedish market – with promises of a stable supply and availability for patients. “What w...

The Future of Swedish & Danish Life Science (2026)

The art of successful licensing – “A lot has to align”

Sharp research, strong data and a high level of innovation are all very good, but more than that is required to achieve the goal of many biotechnology companies...

Charged with illegal pharmaceutical sales – alleged earnings of 23 million

For at least five years, two men allegedly carried out illegal sales of pharmaceuticals and supplements, amassing millions. They are now facing charges at Söder...

Kennedy attackerar dansk vaccinstudie – ”Propagandanummer från läkemedelsindustrin”

USA:s hälsominister Robert F. Kennedy Jr. uppmanar en medicinsk tidskrift att dra tillbaka publiceringen av en stor vaccinstudie, vars slutsatser han ogillar. M...

Positive EMA Decision for BioArctic's New Drug Candidate

Bioarctic's drug candidate for multiple system atrophy, exidavnemab, is recommended to be classified as an orphan drug, according to the European Medicines Agency (EMA).

Leo Pharma to cut 200 jobs and reorganize

Danish Leo Pharma cuts down on staff in its global operations. Around 200 positions will be cut, while 50 will be moved to Poland.

From pharmacist to life science podcaster – Magnus Lejelöv uses his voice as a tool

Magnus Lejelöv has more than 20 years of experience in the pharmaceutical industry and has conducted nearly two hundred interviews with healthcare professionals...

”The importance of stratification in a statistician’s August kitchen”

Ingrid Lönnstedt writes about an experiment of her own at home and about what lessons can be learned from it, in a science column.

GSK pays 2.2 billion dollars to settle Zantac lawsuits

British drugmaker Glaxo Smith Kline, GSK, has struck a 2.2 billion dollar settlement, thereby resolving a vast majority of the liability cases pending against t...

Danish biotech to buy struggling American oncology company

Danish drugmaker Pharmacosmos has agreed to acquire American pharmaceutical company G1 Therapeutics in a deal that amounts to 405 million dollars.

Agreement in the EU on eight years of data exclusivity for new medicines

New pharmaceuticals will be covered by eight years of data exclusivity, according to the proposed new pharmaceutical legislation that EU countries have now agre...

Could an overly burdensome QMS be the organization’s own doing?

Although the above statement is intentionally somewhat provocative, it does hold a degree of truth. Organizations that are generally negative toward regulations...